Get Pharma & Biotech every Monday

One free email with what the biggest companies in Pharma & Biotech filed, were granted and gave up this week.

The Thicket.
Pharma & Biotech / Week of Nov 16, 2026Get it every Monday →
All Pharma & BiotechIssue 001 / Bristol-Myers SquibbThe filing
Bristol-Myers SquibbPublication

Juno Therapeutics publishes application for T cell therapy combined with DGK inhibitor dosing.

The filing

Juno Therapeutics published an application on November 12, 2026, describing a combination therapy for cancer that pairs engineered T cells with a Diacylglycerol kinase (DGK) inhibitor. The company addresses the need for improved persistence and activity of T cells after administration by initiating the DGK inhibitor between Days 1 and 8 of treatment and continuing it until the engineered T cell count peaks. Several claims covering broader dosing ranges and specific chemical structures were cancelled during prosecution, while the remaining claims were amended to specify the timing of inhibitor initiation relative to the T cell infusion.

The claims

USPTO 20260355239A1 / 9 independent claims of 27

  1. Claim 1Currently amended

    A method of treatment, the method comprising administering to a human subject having a cancer a combination therapy for treating a cancer in the subject, the combination therapy comprising: (a) a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein the T cell therapy is administered on Day 1 of the combination therapy; and (b) an inhibitor of DGK a and/or DGK ( , wherein the administration of the inhibitor is initiated on any of Days 1-8, inclusive, of the combination therapy, and the inhibitor is administered once daily for between or between about 21 and 42 consecutive days, inclusive.

  2. Claim 4Currently amended

    A method of treatment, the method comprising administering to a human subject having a cancer a combination therapy for treating a cancer in the subject, the combination therapy comprising: (a) a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein the T cell therapy is administered on Day 1 of the combination therapy; and (b) an inhibitor of DGK a and/or DGK ( , wherein the administration of the inhibitor is initiated on any of Days 1-8, inclusive, of the combination therapy, and the inhibitor is administered continuously at least until the number of engineered T cells of the T cell therapy has peaked in the subject following administration of the T cell therapy.

  3. Claim 5Canceled

    5-20. (Canceled)

  4. Claim 21

    A method of treatment, the method comprising administering to a human subject having a cancer a combination therapy for treating a cancer in the subject, the combination therapy comprising: (a) a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein the T cell therapy is administered on Day 1 of the combination therapy; and (b) an inhibitor of DGK a and/or DGK ( , wherein the administration of the inhibitor is initiated on any of Days 1-8, inclusive, of the combination therapy, and the inhibitor is administered in a plurality of cycles each comprising an administration period in which the inhibitor is administered followed by a rest period during which the inhibitor is not administered.

  5. Claim 25Canceled

    25-29. (Canceled)

  6. Claim 31Canceled

    31-48. (Canceled)

  7. Claim 50Canceled

    50-52. (Canceled)

  8. Claim 70Canceled

    70-74. (Canceled)

  9. Claim 79Canceled

    79-90. (Canceled)

The 18 dependent claims are in the record. Open the record (opens in a new tab)

Expert view

Juno Therapeutics published an application on November 12, 2026, describing a combination therapy for cancer that pairs engineered T cells with a Diacylglycerol kinase (DGK) inhibitor. The company addresses the need for improved persistence and activity of T cells after administration by initiating the DGK inhibitor between Days 1 and 8 of treatment and continuing it until the engineered T cell count peaks. The application covers specific dosing schedules, including daily administration for 21 to 42 days or treatment in cycles with rest periods, and defines the inhibitor as targeting DGK alpha and/or DGK zeta. Several claims covering broader dosing ranges and specific chemical structures were cancelled during prosecution, while the remaining claims were amended to specify the timing of inhibitor initiation relative to the T cell infusion.

Background

The applicant’s account of the prior art / USPTO 20260355239A1

Various strategies are available for T cell therapies, for example administering engineered T cells for adoptive therapy. For example, strategies are available for engineering T cells expressing genetically engineered antigen receptors, such as CAR s or TCRs, and administering compositions containing such cells to subjects. Improved strategies are needed to improve efficacy of the T cells of the cell therapy, for example improving the persistence, activity, and/or proliferation of the cells upon or following administration to subjects. Provided are methods, compositions, uses, and kits that meet such needs. Summar y Provided herein in some embodiments is a method of treatment, the method comprising administering to a subject having a cancer a combination therapy comprising : (a) a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein the T cell therapy is administered on Day 1 of the combination therapy; and (b) an inhibitor of DGK a and/or DGK ( , wherein the administration of the inhibitor is initiated on any of Days 1-8, inclusive, of the combination therapy, and the inhibitor is administered continuously at least until the number of engineered T cells of the T cell therapy has peaked in the subject following administration of the T cell therapy. In some of any embodiments, the administration of the inhibitor is initiated subsequent to the administration of the T cell therapy. Also provided herein in some embodiments is a method of treatment, the method comprising administering to a subject having a cancer an inhibitor of DGK a and/or DGK (, wherein the inhibitor is administered as part of a combination therapy comprising the inhibitor and a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein: prior to initiation of administration of the inhibitor, the subject has been previously administered the T cell therapy, wherein the T cell therapy is administered on Day 1 of the combination therapy; the administration of the inhibitor is initiated on any of Days 1-8, inclusive, of the combination therapy; and the inhibitor is administered continuously at least until the number of engineered T cells of the T cell therapy has peaked in the subject following administration of the T cell therapy. In some of any embodiments, the administration of the inhibitor is initiated on Day 1 of the combination therapy prior to the administration of the T cell therapy. Also provided herein in some embodiments is a method of treatment, the method comprising administering to a subject having a cancer a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein the T cell therapy is administered as part of a combination therapy comprising the T cell therapy and an inhibitor of DGK a and/or DGK ( , wherein : the T cell therapy is administered on Day 1 of the combination therapy; the administration of the inhibitor is initiated on Day 1 of the combination therapy prior to the administration of the T cell therapy; and the inhibitor is administered continuously at least until the number of engineered T cells of the T cell therapy has peaked in the subject following administration of the T cell therapy. In some of any embodiments, the inhibitor is administered daily, once every two days, or once every three days. In some of any embodiments, the inhibitor is administered daily. In some of any embodiments, the inhibitor is administered once on each of the days that the inhibitor is administered. In some of any embodiments, the inhibitor is administered until the number of engineered T cells of the T cell therapy has peaked in the subject following administration of the T cell therapy. In some of any embodiments, the inhibitor is administered over a period of time between or between about 21 and 42 days, inclusive. Also provided herein in some embodiments is a method of treatment, the method comprising administering to a subject having a cancer a combination therapy comprising : (a) a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein the T cell therapy is administered on Day 1 of the combination therapy; and (b) an inhibitor of DGK a and/or DGK ( , wherein the administration of the inhibitor is initiated on any of Days 1-8, inclusive, of the combination therapy, and the inhibitor is administered in a therapeutically effective dose for a period between or between about 21 and 42 days. In some of any embodiments, the administration of the inhibitor is initiated subsequent to the administration of the T cell therapy. Also provided herein in some embodiments is a method of treatment, the method comprising administering to a subject having a cancer an inhibitor of DGK a and/or DGK (, wherein the inhibitor is administered as part of a combination therapy comprising the inhibitor and a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein : prior to initiation of administration of the inhibitor, the subject has been previously administered the T cell therapy, wherein the T cell therapy is administered on Day 1 of the combination therapy; the administration of the inhibitor is initiated on any of Days 1-8, inclusive, of the combination therapy; and the inhibitor is administered in a therapeutically effective dose for a period between or between about 21 and 42 days. In some of any embodiments, the administration of the inhibitor is initiated on Day 1 of the combination therapy prior to the administration of the T cell therapy. Also provided herein in some embodiments is a method of treatment, the method comprising administering to a subject having a cancer a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein the T cell therapy is administered as part of a combination therapy comprising the T cell therapy and an inhibitor of DGK a and/or DGK ( , wherein : the T cell therapy is administered on Day 1 of the combination therapy; the administration of the inhibitor is initiated on Day 1 of the combination therapy prior to the administration of the T cell therapy; and the inhibitor is administered in a therapeutically effective dose for a period between or between about 21 and 42 days. In some of any embodiments, the therapeutically effective dose provides a dose of the inhibitor that is continuously therapeutically effective for the period between or between about 21 and 42 days. In some of any embodiments, the inhibitor is administered every 2 days or 3 days. Also provided herein in some embodiments is a method of treatment, the method comprising administering to a subject having a cancer a combination therapy comprising: (a) a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein the T cell therapy is administered on Day 1 of the combination therapy; and (b) an inhibitor of DGK a and/or DGK ( , wherein the administration of the inhibitor is initiated on any of Days 1-8, inclusive, of the combination therapy, and the inhibitor is administered in a plurality of cycles each comprising an administration period in which the inhibitor is administered followed by a rest period during which the inhibitor is not administered. In some of any embodiments, the administration of the inhibitor is initiated subsequent to the administration of the T cell therapy. Also provided herein in some embodiments is a method of treatment, the method comprising administering to a subject having a cancer an inhibitor of DGK a and/or DGK (, wherein the inhibitor is administered as part of a combination therapy comprising the inhibitor and a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein: prior to initiation of administration of the inhibitor, the subject has been previously administered the T cell therapy, wherein the T cell therapy is administered on Day 1 of the combination therapy; the administration of the inhibitor is initiated on any of Days 1-8, inclusive, of the combination therapy; and the inhibitor is administered in a plurality of cycles each comprising an administration period in which the inhibitor is administered followed by a rest period during which the inhibitor is not administered. In some of any embodiments, during the administration period, the inhibitor is administered daily, every two days, or every three days. In some of any embodiments, during the administration period, the inhibitor is administered daily. In some of any embodiments, during the administration period, the inhibitor is administered once on each of the days that the inhibitor is administered. In some of any embodiments, over the plurality of cycles, the inhibitor is administered until the number of engineered T cells of the T cell therapy has peaked in the subject following administration of the T cell therapy. In some of any embodiments, over the plurality of cycles, the inhibitor is administered over a period of time between or between about 21 and 42 days, inclusive. Also provided herein in some embodiments is a method of treatment, the method comprising administering to a subject having a cancer a combination therapy comprising : (a) a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein the T cell therapy is administered on Day 1 of the combination therapy; and (b) an inhibitor of DGK a and/or DGK ( , wherein the administration of the inhibitor is initiated on any of Days 1-8, inclusive, of the combination therapy, and the inhibitor is administered once daily for between or between about 21 and 42 consecutive days, inclusive. In some of any embodiments, the administration of the inhibitor is initiated subsequent to the administration of the T cell therapy. Also provided herein in some embodiments is a method of treatment, the method comprising administering to a subject having a cancer an inhibitor of DGK a and/or DGK (, wherein the inhibitor is administered as part of a combination therapy comprising the inhibitor and a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein : prior to initiation of administration of the inhibitor, the subject has been previously administered the T cell therapy, wherein the T cell therapy is administered on Day 1 of the combination therapy; the administration of the inhibitor is initiated on any of Days 1-8, inclusive, of the combination therapy; and the inhibitor is administered once daily for between or between about 21 and 42 consecutive days, inclusive. In some of any embodiments, the administration of the inhibitor is initiated on any of Days 1-6, inclusive, of the combination therapy. In some of any embodiments, the administration of the inhibitor is initiated on any of Days 1-4, inclusive, of the combination therapy. In some of any embodiments, the administration of the inhibitor is initiated on Day 1 or Day 2 of the combination therapy. In some of any embodiments, the administration of the inhibitor is initiated on Day 1 of the combination therapy. In some of any embodiments, the administration of the inhibitor is initiated on Day 1 of the combination therapy prior to the administration of the T cell therapy. Also provided herein in some embodiments is a method of treatment, the method comprising administering to a subject having a cancer a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein the T cell therapy is administered as part of a combination therapy comprising the T cell therapy and an inhibitor of DGK a and/or DGK ( , wherein : the T cell therapy is administered on Day 1 of the combination therapy; the administration of the inhibitor is initiated on Day 1 of the combination therapy prior to the administration of the T cell therapy; and the inhibitor is administered once daily for between or between about 21 and 42 consecutive days, inclusive. In some of any embodiments, the inhibitor is administered over a period of time between or between about 21 and 35 days, inclusive. In some of any embodiments, the inhibitor is administered over a period of time between or between about 21 and 28 days, inclusive. In some of any embodiments, the inhibitor is administered over a period of time between or between about 28 and 42 days, inclusive. In some of any embodiments, the inhibitor is administered over a period of time between or between about 28 and 35 days, inclusive. In some of any embodiments, the inhibitor is administered over a period of time that is or is about 28 days. In some of any embodiments, the inhibitor is administered over a period of time that is or is about 30 days. In some of any embodiments, over the plurality of cycles, the inhibitor is administered over a period of time between or between about 21 and 35 days, inclusive. In some of any embodiments, over the plurality of cycles, the inhibitor is administered over a period of time between or between about 21 and 28 days, inclusive. In some of any embodiments, over the plurality of cycles, the inhibitor is administered over a period of time between or between about 28 and 42 days, inclusive. In some of any embodiments, over the plurality of cycles, the inhibitor is administered over a period of time between or between about 28 and 35 days, inclusive. In some of any embodiments, over the plurality of cycles, the inhibitor is administered over a period of time that is or is about 28 days. In some of any embodiments, over the plurality of cycles, the inhibitor is administered over a period of time that is or is about 30 days. In some of any embodiments, the inhibitor is administered once daily for between or between about 21 and 35 consecutive days, inclusive. In some of any embodiments, the inhibitor is administered once daily for between or between about 21 and 28 consecutive days, inclusive. In some of any embodiments, the inhibitor is administered once daily for between or between about 28 and 42 consecutive days, inclusive. In some of any embodiments, the inhibitor is administered once daily for between or between about 28 and 35 consecutive days, inclusive. In some of any embodiments, the inhibitor is administered once daily for or for about 28 consecutive days. Also provided herein in some embodiments is amethod of treatment, the method comprising administering to a subject having a cancer a combination therapy comprising : (a) a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein the T cell therapy is administered on Day 1 of the combination therapy; and (b) an inhibitor of DGK a and/or DGK ( , wherein the administration of the inhibitor is initiated on Day 1 of the combination therapy, and the inhibitor is administered once daily on Days 1-28, inclusive, of the combination therapy. In some of any embodiments, the administration of the inhibitor is initiated subsequent to the administration of the T cell therapy. Also provided herein in some embodiments is a method of treatment, the method comprising administering to a subject having a cancer an inhibitor of DGK a and/or DGK (, wherein the inhibitor is administered as part of a combination therapy comprising the inhibitor and a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein : prior to initiation of administration of the inhibitor, the subject has been previously administered the T cell therapy, wherein the T cell therapy is administered on Day 1 of the combination therapy; the administration of the inhibitor is initiated on Day 1 of the combination therapy; and the inhibitor is administered once daily on Days 1-28, inclusive, of the combination therapy. In some of any embodiments, the administration of the inhibitor is initiated prior to the administration of the T cell therapy. Also provided herein in some embodiments is a method of treatment, the method comprising administering to a subject having a cancer a T cell therapy comprising viable engineered T cells expressing a recombinant receptor directed against an antigen expressed by cells of the cancer, wherein the T cell therapy is administered as part of a combination therapy comprising the T cell therapy and an inhibitor of DGK a and/or DGK ( , wherein : the T cell therapy is administered on Day 1 of the combination therapy; the administration of the inhibitor is initiated on Day 1 of the combination therapy prior to the administration of the T cell therapy; and the inhibitor is administered once daily on Days 1-28, inclusive, of the combination therapy. In some of any embodiments, the inhibitor is administered once daily on Days 1-30, inclusive, of the combination therapy. In some of any embodiments, the administration of the inhibitor is initiated within or within about 12 hours of the administration of the T cell therapy. In some of any embodiments, the administration of the inhibitor is initiated within or within about 6 hours of the administration of the T cell therapy. In some of any embodiments, the administration of the inhibitor is initiated within or within about 4 hours of the administration of the T cell therapy. In some of any embodiments, the administration of the inhibitor is initiated within or within about 2 hours of the administration of the T cell therapy. In some of any embodiments, the administration of the inhibitor is initiated within or within about 1 hour of the administration of the T cell therapy. In some of any embodiments, the administration of the inhibitor is initiated on Day 1 of the combination therapy concurrently with the administration of the T cell therapy. In some of any embodiments, the administration of the inhibitor is initiated on Day 1 of the combination therapy during the administration of the T cell therapy. In some of any embodiments, prior to the administration of the T cell therapy, the subject has been preconditioned with a lymphodepleting therapy comprising administration of fludarabine and/or cyclophosphamide. In some of any embodiments, prior to the administration of the T cell therapy, the subject has been preconditioned with a lymphodepleting therapy comprising administration of fludarabine and cyclophosphamide. In some of any embodiments, the method further comprises administering the lymphodepleting therapy to the subject. In some of any embodiments, the lymphodepleting therapy comprises administration of: cyclophosphamide at between or between about 200 and 400 mg/ m 2 , inclusive, daily for between or between about 2 and 4 days, inclusive; and/or fludarabine at between or between about 20 and 40 mg/ m 2 , inclusive, daily for between or between about 2 and 4 days, inclusive. In some of any embodiments, the lymphodepleting therapy comprises administration of cyclophosphamide at between or between about 200 and 400 mg/ m 2 , inclusive, daily for between or between about 2 and 4 days, inclusive. In some of any embodiments, the lymphodepleting therapy comprises administration of fludarabine at between or between about 20 and 40 mg/ m 2 , inclusive, daily for between or between about 2 and 4 days, i

The record continues: read the full text (opens in a new tab)

Get Pharma & Biotech every Monday.

© 2026 Fearn AI, Inc. All rights reserved.

Information from the public patent record, not legal advice.

Big Law patents. In plain sight.

The all-in-one patent firm for startups. Former Big Law patent experts and PhDs, on AI that runs on our own GPUs.

Social

Newsletter

Stay updated on the future of intellectual property.

Fearn Legal, LLC is a patent prosecution firm, licensed to file and prosecute patents across the USPTO. The information provided here is for general informational purposes only and does not constitute legal advice. Viewing this information or contacting us through this website does not create an attorney-client or patent agent-client relationship. For personalized legal advice, please reach out to us directly to set up a legal consult or consult directly with a qualified attorney.

Big Law patents. In plain sight.

Social

Newsletter

Stay updated on the future of intellectual property.

Fearn Legal, LLC is a patent prosecution firm, licensed to file and prosecute patents across the USPTO. The information provided here is for general informational purposes only and does not constitute legal advice. Viewing this information or contacting us through this website does not create an attorney-client or patent agent-client relationship. For personalized legal advice, please reach out to us directly to set up a legal consult or consult directly with a qualified attorney.

Big Law patents. In plain sight.

The all-in-one patent firm for startups. Former Big Law patent experts and PhDs, on AI that runs on our own GPUs.

Social

Newsletter

Stay updated on the future of intellectual property.

Fearn Legal, LLC is a patent prosecution firm, licensed to file and prosecute patents across the USPTO. The information provided here is for general informational purposes only and does not constitute legal advice. Viewing this information or contacting us through this website does not create an attorney-client or patent agent-client relationship. For personalized legal advice, please reach out to us directly to set up a legal consult or consult directly with a qualified attorney.